Markers associated with human double minute 2 inhibitors

摘要

The invention provides methods of monitoring differential gene expression of biomarkers to determine patient sensitivity to Human Double Minute inhibitors (MDM2i), methods of determining the sensitivity of a cell to an MDM2i by measuring biomarkers and methods of screening for candidate MDM2i.

主权项

1. A method of treating a cancer patient comprising:
a) measuring differential gene expression of the biomarkers MDM2, CDKN1A, ZMAT3, DDB2, FDXR, RPS27L, BAX, RRM2B, SESN1, CCNG1, XPC, TNFRSF1OB and AEN in a cancer sample obtained from the patient; b) determining differential expression of the biomarkers by comparing the measured gene expression of the biomarkers in the cancer sample with the gene expression of the biomarkers in a control sample, wherein the control sample has a functional p53 gene pathway; c) determining sensitivity of the patient to a MDM2i(1); and d) administering to the patient MDM2i(1); (e) wherein the cancer sample is selected from the group consisting of breast, lung, pancreas, colon, liver, leukemia, melanoma and kidney.